At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 673 enrolled
Drug / intervention
adalimumab +1 morebiological
Likely dose
adalimumab 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis
In Brief
A Phase 3 clinical trial evaluating adalimumab and Placebo for Axial Spondyloarthritis. Completed, enrolled 673 participants.
Detailed Summary
The objective of this multicenter, randomized, double-blind study was to evaluate the efficacy and safety of continuing versus withdrawing therapy with adalimumab 40 mg given every other week SC in maintaining remission in subjects with moderate to severe non-radiographic axial spondyloarthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAxial Spondyloarthritis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 2013
Enrollment StartApr 2013
Primary CompletionFeb 2017
Study CompletionApr 2017
TodayJul 2026
First PostedMar 11, 2013
Enrollment StartApr 16, 2013
Primary CompletionFeb 21, 2017
Study CompletionApr 14, 2017
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.3 years ago
Interventions
adalimumabbiological
40 mg every other week
Placebobiological
every other week